MEI Pharma Inc (NASDAQ:MEIP) — Market Cap & Net Worth
Market Cap & Net Worth: MEI Pharma Inc (MEIP)
MEI Pharma Inc (NASDAQ:MEIP) has a market capitalization of $100.81 Million ($100.81 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19158 globally and #4207 in its home market, demonstrating a -36.70% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MEI Pharma Inc's stock price $3.07 by its total outstanding shares 32837700 (32.84 Million). Analyse MEI Pharma Inc (MEIP) cash flow conversion to see how efficiently the company converts income to cash.
MEI Pharma Inc Market Cap History: 2015 to 2025
MEI Pharma Inc's market capitalization history from 2015 to 2025. Data shows change from $816.25 Million to $100.81 Million (-19.86% CAGR).
Index Memberships
MEI Pharma Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #547 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1871 of 3165 |
Weight: MEI Pharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
MEI Pharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MEI Pharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.24x
MEI Pharma Inc's market cap is 1.24 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.54x
MEI Pharma Inc's market cap is 4.54 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.07 Billion | $23.25 Million | $2.67 Million | 46.08x | 401.25x |
| 2018 | $1.35 Billion | $1.62 Million | -$40.07 Million | 830.34x | N/A |
| 2019 | $1.27 Billion | $4.92 Million | -$16.82 Million | 257.41x | N/A |
| 2020 | $1.35 Billion | $28.91 Million | -$47.17 Million | 46.58x | N/A |
| 2021 | $1.36 Billion | $25.54 Million | -$41.31 Million | 53.34x | N/A |
| 2022 | $124.27 Million | $40.70 Million | -$54.45 Million | 3.05x | N/A |
| 2023 | $190.46 Million | $48.82 Million | -$31.84 Million | 3.90x | N/A |
| 2024 | $80.78 Million | $65.30 Million | $17.78 Million | 1.24x | 4.54x |
Competitor Companies of MEIP by Market Capitalization
Companies near MEI Pharma Inc in the global market cap rankings as of May 4, 2026.
Key companies related to MEI Pharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
MEI Pharma Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, MEI Pharma Inc's market cap moved from $816.25 Million to $ 100.81 Million, with a yearly change of -19.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $100.81 Million | +24.80% |
| 2024 | $80.78 Million | -57.59% |
| 2023 | $190.46 Million | +53.26% |
| 2022 | $124.27 Million | -90.88% |
| 2021 | $1.36 Billion | +1.14% |
| 2020 | $1.35 Billion | +6.45% |
| 2019 | $1.27 Billion | -6.06% |
| 2018 | $1.35 Billion | +25.71% |
| 2017 | $1.07 Billion | +45.83% |
| 2016 | $734.63 Million | -10.00% |
| 2015 | $816.25 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of MEI Pharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $100.81 Million USD |
| MoneyControl | $100.81 Million USD |
| MarketWatch | $100.81 Million USD |
| marketcap.company | $100.81 Million USD |
| Reuters | $100.81 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MEI Pharma Inc
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, … Read more